Oxford+

Hosted by Susannah de Jager

Business InvestingInterviews guests

Website RSS feed LinkedIn

Episodes

Latest episode

Jun 2026

Language

About the show

Welcome to Oxford+, the podcast series that explores the myths and truths of the Oxford investing landscape hosted by Susannah de Jager. Since moving to Oxford, Susannah has collaborated with experts, entrepreneurs, and government to shape the conversation around domestic scale-up capital. Oxford+ aims to inform, inspire, and connect. We'll talk to Founders, investors, academics, politicians, and facilitators and explore how Oxford is open for business.

Listen to episodes

57 recent

June 16, 2026Episode 106 min

Oxford+ in Brief with Ceri Morgan, Partner at Dalloway Partners

How should we measure success in the place trying to scale Britain's best science? In this Oxford+ in Brief, Dr Ceri Morgan takes on the same four quick-fire questions every guest faces. She reflects on what success would mean after two decades spent at arm's length in investment banking, the advice she would give anyone entering the Oxford ecosystem, and what the city does brilliantly yet struggles with: it brings you face to face with astonishing, modest people, but connects them far too rarely. Looking ahead to 2050, Ceri wants Oxford closer to the Boston benchmark, with more companies scaling outside the university and acquirers reinvesting locally rather than draining talent abroad. Her timing is apt: UK university spin-outs have nearly tripled in value to £49 billion since 2020, with activity now spreading beyond the golden triangle. From mentorship and the Lamb and Flag to a magic-wand investor database, this is a short, candid window into how a natural connector thinks.Ceri Morgan: Dr Ceri Morgan is a Partner at Dalloway Partners, the advisory firm founded in 2025 by Vanessa Colomar and Helen James to help foundational science and first-time founders scale at speed. A medical doctor by training, she practised in cardiology and trauma medicine before moving into the City, where she spent more than two decades in healthcare and life sciences investment banking, building and leading top-ranked life science teams at firms including KBC Peel Hunt and Deutsche Bank and advising companies such as Oxford Nanopore and IP Group. Most recently she was Head of Late Stage Portfolio at Oxford Science Enterprises, and she is a Senior Advisor to LifeScience ORG. Based in Oxford, she also sits on a London hospital patient advisory group, drawing on her own experience as a cancer patient to push for stronger patient advocacy.Connect with Ceri on LinkedInSusannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

June 9, 2026Episode 1039 min

Recycling Capital and Talent in Oxford's Innovation Economy

How should we value a healthcare system that frustrates the very innovators trying to improve it?In this episode of Oxford+, host Susannah de Jager speaks with Dr Ceri Morgan, a doctor turned healthcare investment banker turned patient, about her three careers and what they reveal about UK life sciences. Ceri explains why, for years, companies pitching an NHS-first strategy were handed close to a zero valuation, and why the UK's thin life sciences public market has pushed founders towards private capital and trade sales.Her move to Dalloway Partners marks a third act focused on the non-scientific side of scaling: mentoring founders, opening up investor networks and building Oxford's ecosystem. The timing matters. After UK biotech raised just £1.8 billion in 2025, early 2026 figures show venture funding rebounding, with £516 million raised in the first quarter. From recycling capital and talent to being your own patient advocate, this is a candid conversation about fixing the structures around brilliant British science.(00:00) - Welcome to Oxford+ (01:23) - A Doctor's Path into the City (03:34) - Building a Life Sciences Banking Team (06:31) - Twenty Years Advising Science Companies (08:35) - A Third Career and a New Mission (10:24) - Why the NHS Earns a Zero Valuation (11:53) - The Shrinking Life Sciences Public Market (15:29) - Inside Dalloway Partners (17:27) - The Non-Scientific Side of Scaling (22:32) - Treating Oxford as One Ecosystem (27:46) - Female Health, Storytelling and Open Networks (33:58) - Being Your Own Patient Advocate Ceri Morgan: Dr Ceri Morgan is a Partner at Dalloway Partners, the advisory firm founded in 2025 by Vanessa Colomar and Helen James to help foundational science and first-time founders scale at speed. A medical doctor by training, she practised in cardiology and trauma medicine before moving into the City, where she spent more than two decades in healthcare and life sciences investment banking, building and leading top-ranked life science teams at firms including KBC Peel Hunt and Deutsche Bank and advising companies such as Oxford Nanopore and IP Group. Most recently she was Head of Late Stage Portfolio at Oxford Science Enterprises, and she is a Senior Advisor to LifeScience ORG. Based in Oxford, she also sits on a London hospital patient advisory group, drawing on her own experience as a cancer patient to push for stronger patient advocacy.Connect with Ceri on LinkedIn Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

June 2, 2026Episode 95 min

Oxford+ in Brief with Riham Satti, co-founder and CEO of MeVitae

What does success really look like when we get hiring right? In this Oxford+ in Brief, Susannah de Jager puts forward four questions to Riham Satti, co-founder and CEO of MeVitae. Riham describes success as a workplace where people feel they belong, feel empowered, and stay because their work feels like a career worth building. She offers candid advice for anyone entering the Oxford ecosystem, reflects on what the city does brilliantly and where it could connect its specialised pockets more effectively, and imagines what Oxford might look like by 2050. With a recent large-scale study finding that AI hiring tools can systematically reject qualified candidates (Stanford HAI, May 2026), her closing wish, a magic wand for fairness at work, could not feel more timely. Riham Satti: Riham Satti is the co-founder and CEO of MeVitae, an award-winning people intelligence platform that combines neuroscience, behavioural economics, and responsible AI to help organisations make fairer, faster, and fully explainable workforce decisions. A neuroscientist by training, Riham studied medical engineering at Imperial College London before completing her research at Oxford, where she developed a deep fascination with how the brain makes decisions. Through the Oxford University Innovation incubator, she co-founded MeVitae with computer scientist Vivek Doraiswamy to tackle bias and inefficiency in hiring. MeVitae now works with global enterprise clients including Transport for London, HS2, and Taylor Wessing, delivering up to 90% time and cost savings while reducing employee turnover by 25%. The company has been honoured with the Norrsken Impact/100 Award, nominated by Microsoft, and was selected by the UK Information Commissioner's Office to co-develop the national AI Data Protection Audit. Riham is a TEDx and keynote speaker and sits on the TechUK Council, advising on the responsible use of AI in business.Connect with Riham on LinkedInSusannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

May 26, 2026Episode 941 min

Unconscious Bias, Responsible AI, and the Future of Workforce Decisions

What if the key to fairer hiring lies not in better policies, but in understanding how our brains actually make decisions?In this episode of Oxford+, host Susannah de Jager speaks with Riham Satti, co-founder and CEO of MeVitae, about her journey from studying neuroscience at Oxford to building an AI-driven platform that transforms workforce decision-making. They explore how cognitive biases shape recruitment, why ten seconds of CV screening can derail a hiring process, and how organisations can use data and responsible AI to make fairer, faster, and smarter people decisions.With recent research showing that recruiters using biased AI tools mirror those inequitable choices up to 90% of the time, the conversation could not be more timely. Riham explains how MeVitae integrates neuroscience, anonymised recruiting, and transparent algorithms to help organisations identify hidden risks, improve candidate experience, and build genuinely inclusive workplaces. From bootstrapping with grant funding to working with global enterprise clients, her story is a blueprint for turning academic curiosity into commercial impact.(00:00) - Welcome to Oxford Plus (01:42) - The Academic Path to Entrepreneurship (03:12) - Stumbling into the World of Startups (04:21) - From a CV App to Uncovering a Broken Industry (06:37) - Funding the Early Days with Grants and Grit (09:59) - How MeVitae Evolved from B2C to Enterprise AI (13:58) - Neuroscience in Action: Eye Tracking and Hiring Bias (15:55) - Practical Steps to Reduce Unconscious Bias (22:16) - The Benefits Beyond Efficiency: Candidate Experience (27:48) - Connecting HR Data to Uncover Hidden Risks (32:12) - Company Retreats and Building Team Culture (37:01) - The Future of MeVitae and Responsible AI Riham Satti: Riham Satti is the co-founder and CEO of MeVitae, an award-winning people intelligence platform that combines neuroscience, behavioural economics, and responsible AI to help organisations make fairer, faster, and fully explainable workforce decisions. A neuroscientist by training, Riham studied medical engineering at Imperial College London before completing her research at Oxford, where she developed a deep fascination with how the brain makes decisions. Through the Oxford University Innovation incubator, she co-founded MeVitae with computer scientist Vivek Doraiswamy to tackle bias and inefficiency in hiring. MeVitae now works with global enterprise clients including Transport for London, HS2, and Taylor Wessing, delivering up to 90% time and cost savings while reducing employee turnover by 25%. The company has been honoured with the Norrsken Impact/100 Award, nominated by Microsoft, and was selected by the UK Information Commissioner's Office to co-develop the national AI Data Protection Audit. Riham is a TEDx and keynote speaker and sits on the TechUK Council, advising on the responsible use of AI in business.Connect with Riham on LinkedIn Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

May 19, 2026Episode 89 min

Oxford+ in Brief with Dr Holly Reeve, co-founder and CEO of HydRegen

What would it take for Oxford to truly unlock its potential as a global innovation hub and what keeps getting in the way?In this Oxford+ In Brief mini episode, host Susannah de Jager puts four quick-fire questions to Dr Holly Reeve, co-founder and CEO of HydRegen. Holly shares what success looks like if Hydregen reaches commercial scale manufacturing, why Oxford's chemistry department has become a breeding ground for spin-outs, and why she wishes the barriers between universities and startups were far lower than they are today.With a new super cluster board forming across the Oxford–Cambridge arc and initiatives like Equinox and OX Tech Week working to connect the ecosystem, Holly argues the direction of travel is encouraging. But she is clear that the real bottleneck is not facilities or funding structures: it is the failure to invest strategically in the people behind the science. Dr Holly Reeve: Holly Reeve is the co-founder and CEO of HydRegen, an Oxford University spin-out developing bio-based catalysts to replace precious metals in chemical manufacturing. She holds a MChem and DPhil in Inorganic Chemistry from the University of Oxford, where she worked on the HydRegen technologies from inception in Professor Kylie Vincent's research group. Holly has raised over £1.3 million in early-stage funding from Innovate UK and investors, secured a further £2.6 million led by Clean Growth Fund, and grown the company to 15 people. She is a Royal Society of Chemistry Emerging Technology prize winner and a member of the Royal Academy of Engineering Enterprise Hub's Shott Scale Up Accelerator. In June 2025, HydRegen announced a strategic collaboration with James Robinson Speciality Ingredients to implement its Bio2Amine™ biocatalyst technology in commercial manufacturing.Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

May 12, 2026Episode 836 min

Bridging the Gap between Scientific Research and Industrial Impact

What does it really take to turn a breakthrough in a university lab into a company that could transform how the world makes chemicals?In this episode of Oxford+, host Susannah de Jager speaks with Dr Holly Reeve, co-founder and CEO of HydRegen, an Oxford spin-out replacing precious metals in chemical manufacturing with bio-based enzyme catalysts. Holly shares her journey from a farm in rural England to leading a 15-person deep tech company now preparing for manufacturing and raising a Series A.With the global biocatalysis market projected to more than double to USD 10.2 billion by 2033, Hydregen is positioned at the forefront of a sector gaining serious momentum. Holly discusses how she developed leadership skills during her PhD, why the shift from academic to commercial mindset is so difficult, and how she balances curiosity with execution. She also speaks candidly about the challenges of fundraising as a female founder in a sector where women-led deep tech startups still receive only 15% of seed funding.(00:00) - Welcome to Oxford+ (01:22) - Growing Up Curious on a Farm (02:36) - Finding Chemistry at Oxford (04:17) - Inside Kylie Vincent's Research Group (05:17) - Learning to Lead through Delegation (07:16) - Going beyond the Lab to Find Industry (09:00) - Knowing Your Strengths and Building around Them (12:13) - Building Industry Relationships during a PhD (13:43) - Learning to Listen before You Pitch (18:06) - Founding HydRegen (23:57) - Replacing Precious Metals with Bio-based Catalysts (31:19) - Exploration versus Exploitation in Deep Tech Dr Holly Reeve: Holly Reeve is the co-founder and CEO of Hydregen, an Oxford University spin-out developing bio-based catalysts to replace precious metals in chemical manufacturing. She holds a MChem and DPhil in Inorganic Chemistry from the University of Oxford, where she worked on the HydRegen technologies from inception in Professor Kylie Vincent's research group. Holly has raised over £1.3 million in early-stage funding from Innovate UK and investors, secured a further £2.6 million led by Clean Growth Fund, and grown the company to 15 people. She is a Royal Society of Chemistry Emerging Technology prize winner and a member of the Royal Academy of Engineering Enterprise Hub's Shott Scale Up Accelerator. In June 2025, HydRegen announced a strategic collaboration with James Robinson Speciality Ingredients to implement its Bio2Amine™ biocatalyst technology in commercial manufacturing.Connect with Holly on LinkedInSusannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

May 5, 2026Episode 73 min

Oxford+ in Brief with Dr Christiaan de Koning and Michael Collyer, Co-Founders of Founders and Funders

What does success really look like for Oxford's innovation ecosystem, and how do you build something that lasts?In this Oxford+ in Brief bonus episode, host Susannah de Jager puts the same four questions to Dr Christiaan de Koning and Michael Collyer, co-founders of Founders and Funders and the team behind the inaugural OX Tech Week. With UK startups raising $7.8 billion in Q1 2026 alone, the stakes for getting Oxford's commercialisation engine right have never been higher. Looking ahead to 2050, Christiaan and Michael imagine a less fragmented, more collaborative Oxford that is not just a research hub but a global commercial centre for science and innovation.Dr Christiaan de Koning: Christiaan de Koning is an Associate Fellow at Green Templeton College, University of Oxford, and Chair of the Founders and Funders Foundation. He teaches at Said Business School and is a strategic adviser to CIMMYT, the International Maize and Wheat Improvement Centre. He holds a DPhil from Oxford in management research, where his work focused on the commercialisation of CRISPR biotechnology through new ventures. Through Founders and Funders, he has helped build a community of over 4,000 members connecting researchers, entrepreneurs, and investors across the Oxford ecosystem.Connect with Christiaan on LinkedInMichael Collyer: Michael Collyer is a researcher at the University of Oxford's Internet Institute and co-founder of the Founders and Funders Foundation. He co-established the university's AI network, running events in Oxford and London to connect researchers and entrepreneurs in the AI and machine learning space. His academic work spans information controls, natural language processing, machine learning, and the intersection of artificial intelligence with intellectual property law.Connect with Michael Collyer on LinkedInSusannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

April 28, 2026Episode 726 min

OX Tech Week: From Pub Meetups to a City-Wide Tech Festival

What would it take for Oxford to rival Silicon Valley or Boston as a global destination for deep tech?In this episode of Oxford Plus, host Susannah de Jager sits down with Dr Christiaan de Koning and Michael Collyer, co-founders of the Founders and Funders community, to explore how Oxford is organising itself for a new chapter in innovation. What started as a small gathering during COVID has grown into a 4,000-strong network and a registered foundation connecting researchers, founders, investors, and institutions across the city.Now, with UK startup funding reaching $7.8 billion in Q1 2026 alone – a 60% increase year on year, Oxford is well placed to capture a growing share of that momentum. Christiaan and Michael discuss why the city's problem is not a lack of capital or talent but a lack of connection, and how their upcoming OX Tech Week aims to change that by creating a visible, city-wide platform for the ecosystem.From the Oxford Innovation Map to the vision of making Oxford the global home of deep tech, this is a conversation about what happens when a city that has always excelled at discovery starts to organise itself around building, scaling, and global relevance.Founders and Funders – Oxford's community foundation for researchers, founders, and investorsOxford Tech Week – Oxford's inaugural city-wide tech festival, 26–29 May 2026Oxford Innovation Map (oxmap.tech) – Interactive map of Oxford-affiliated startups, investors, and innovation hubs(00:00) - Welcome to Oxford Plus (01:09) - Introducing Oxford Tech Week and Founders and Funders (02:17) - How Founders and Funders Began (04:40) - From Online Events to Packed Pubs (06:24) - Why 97% of STEM PhDs Leave Academia (08:09) - Oxford at an Inflection Point (10:08) - The Missing Front Door to Oxford (11:06) - Mapping Oxford's Innovation Ecosystem (13:14) - More than Just a University Town (15:53) - The Capital Is Already Here (19:57) - Inside the Inaugural Oxford Tech Week (25:14) - A North Star for Deep Tech Dr Christiaan de Koning: Christiaan de Koning is an Associate Fellow at Green Templeton College, University of Oxford, and Chair of the Founders and Funders Foundation. He teaches at Said Business School and is a strategic adviser to CIMMYT, the International Maize and Wheat Improvement Centre. He holds a DPhil from Oxford in management research, where his work focused on the commercialisation of CRISPR biotechnology through new ventures. Through Founders and Funders, he has helped build a community of over 4,000 members connecting researchers, entrepreneurs, and investors across the Oxford ecosystem.Connect with Christiaan on LinkedInMichael Collyer: Michael Collyer is a researcher at the University of Oxford's Internet Institute and co-founder of the Founders and Funders Foundation. He co-established the university's AI network, running events in Oxford and London to connect researchers and entrepreneurs in the AI and machine learning space. His academic work spans information controls, natural language processing, machine learning, and the intersection of artificial intelligence with intellectual property law.Connect with Michael Collyer on LinkedInSusannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

April 21, 2026Episode 611 min

Oxford+ in Brief with Benny Axt, Entrepreneur in Residence at Oxford Science Enterprises

What would it take for Oxford to become the place where the companies that define global healthcare are actually built?In this Oxford+ in Brief, host Susannah de Jager puts four quick-fire questions to Benny Axt, Entrepreneur in Residence at Oxford Science Enterprises. Benny shares his vision of success for the ecosystem, his advice for newcomers, and a candid assessment of where Oxford excels and where it falls short. He argues that world-class science alone is not enough, speed of translation, commercial talent, growth capital and a cultural shift towards risk-taking are all essential if Oxford is to fulfil its potential.With Deloitte's 2026 Global Health Care Outlook reporting that over 70 per cent of non-US health system executives expect margins to improve this year, and IQVIA highlighting structural shifts across the NHS that are reshaping the landscape for health tech companies, Benny's call for Oxford to optimise for execution over perfection feels especially timely. From express licensing of bundled IP to unlocking pension fund capital, this is a concise and direct take on what needs to change, and why the UK's first trillion-dollar company could emerge from deep science in Oxford.Benny Axt: Benny Axt is Entrepreneur in Residence in the Health Tech team at Oxford Science Enterprises (OSE), the largest university-affiliated investment company in the world and OSE's first EIR to join from the US. A seasoned healthcare strategist, operator and corporate development leader, Benny has spent over 15 years building healthcare businesses across six continents. Previously Vice President of Strategy at Dialogue Health Technologies Inc., he supported the company's US market entrance and helped grow it from a venture-backed startup through to IPO and acquisition. Before that, Benny held leadership roles at DaVita, a Fortune 500 healthcare provider, where his work included leading the privatisation of healthcare services in Saudi Arabia and building cultural infrastructure across more than a dozen countries. Benny holds an MBA and a Master of Health Care Delivery Science from Dartmouth College. In addition to his role in venture capital, he serves as a board advisor and healthcare consultant to leaders seeking guidance on strategy, operations and international expansion.Connect with Benny on LinkedInSusannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.

April 14, 2026Episode 649 min

Healthcare Innovation When Lives Are at Stake

How does world-class science fail to become a scalable business and what can founders do about it?In this episode of Oxford+, host Susannah de Jager speaks with Benny Axt, Entrepreneur in Residence at Oxford Science Enterprises, about the complex relationship between healthcare technology and the systems it must operate within. They explore why healthcare's apparent inefficiency is often intentional constraint, how reimbursement models and regulatory pathways can make or break a company, and what UK health tech founders consistently underestimate about the US market.Drawing on a recent BCG report highlighting a £20 billion annual opportunity if the UK strengthens its ability to translate research into real-world solutions, the conversation underscores why system fluency is not optional but essential. From the cultural transformation Benny led at DaVita across a dozen countries to the structural realities of NHS adoption and the perverse incentives within US oncology, this episode offers a candid and practical guide for founders, investors and anyone working at the intersection of innovation and healthcare delivery.(00:00) - Welcome to Oxford+ (01:51) - The Biggest Misconception about Healthcare (05:04) - Technology versus System: Where Value Really Comes From (07:16) - When Extraordinary Science Fails to Translate (11:48) - The GLP-1 Revolution and Its Unintended Consequences (15:02) - Four Constants across Global Healthcare Systems (18:24) - Culture, DaVita, and Scaling Values across Continents (24:21) - What UK Founders Get Wrong about the US Market (28:12) - Replacement versus Net New Cost Centres (30:48) - Advising Oxford Spin-Outs in Their First 18 Months (38:05) - What Excites Benny about Oxford's Health Tech Ecosystem (44:03) - Why Oxford Science Enterprises and Why Now Benny Axt: Benny Axt is Entrepreneur in Residence in the Health Tech team at Oxford Science Enterprises (OSE), the largest university-affiliated investment company in the world and OSE's first EIR to join from the US. A seasoned healthcare strategist, operator and corporate development leader, Benny has spent over 15 years building healthcare businesses across six continents. Previously Vice President of Strategy at Dialogue Health Technologies Inc., he supported the company's US market entrance and helped grow it from a venture-backed startup through to IPO and acquisition. Before that, Benny held leadership roles at DaVita, a Fortune 500 healthcare provider, where his work included leading the privatisation of healthcare services in Saudi Arabia and building cultural infrastructure across more than a dozen countries. Benny holds an MBA and a Master of Health Care Delivery Science from Dartmouth College. In addition to his role in venture capital, he serves as a board advisor and healthcare consultant to leaders seeking guidance on strategy, operations and international expansion.Connect with Benny on LinkedInSusannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.Connect with Susannah on LinkedIn and Subscribe to the Oxford+ Newsletter for Exclusive ContentOxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya, HSBC Innovation Banking, and James Cowper Kreston.Produced and Edited by Story Ninety-Four in Oxford.